Overview

Trial to Assess Chelation Therapy 2

Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Trial to Assess Chelation Therapy 2 (TACT2) is a randomized, double blind controlled factorial clinical trial of edetate disodium-based chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction (MI).
Phase:
Phase 3
Details
Lead Sponsor:
Mt. Sinai Medical Center, Miami
Collaborators:
Duke Clinical Research Institute
National Center for Complementary and Integrative Health (NCCIH)
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Edetic Acid
Pentetic Acid
Vitamins